Eupraxia pharmaceuticals inc EPRX.US Overview Analysis
EPRX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
EPRX Current Performance
1.25%
Eupraxia pharmaceuticals inc
-3.92%
Avg of Sector
-0.77%
S&P500
Top 10 High Relevance to EPRX
- QNCX Quince therapeutics incValue 3Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
EPRX Profile
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company's lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.